Metformin is one of the most commonly prescribed medications for the treatment of type 2
diabetes. Numerous reports have suggested potential anti-cancerous and cancer preventive …

The deregulation of energetic and cellular metabolism is a signature of cancer cells. Thus,
drugs targeting cancer cell metabolism may have promising therapeutic potential. Previous …

Repurposing metformin for cancer therapy is attractive due to its safety profile,
epidemiological evidence, and encouraging data from human clinical trials. Although it is …

Metformin has been extensively studied for its impact on cancer cell metabolism and
anticancer potential. Despite evidence of significant reduction in cancer occurrence in …

Tumor heterogeneity impinges on all the aspects of tumor history, from onset to metastasis
and relapse. It is growingly recognized as a propelling force for tumor adaptation to …

Metformin has been a first-line treatment for type II diabetes mellitus for decades and is the
most widely prescribed antidiabetic drug. Retrospective studies have found that metformin …

Metformin is the first-line treatment for type 2 diabetes. Results from several clinical studies
have indicated that type 2 diabetic patients treated with metformin might have a lower cancer …

Cancer cells exhibit altered metabolism, a phenomenon described a century ago by Otto
Warburg. However, metabolic drug targeting is considered an underutilized and poorly …

Late-phase clinical trials investigating metformin as a cancer therapy are underway.
However, there remains controversy as to the mode of action of metformin in tumors at …

Cancer metabolism is the focus of intense research, which witnesses its key role in human
tumors. Diabetic patients treated with metformin exhibit a reduced incidence of cancer and …